Failed to Meet Primary Endpoint in 57-Patient PoC Trial
Development Continues for Graves' Disease, Rheumatoid Arthritis, and Other Indications

HanAll Biopharma's next-generation autoimmune disease treatment 'IMVT-1402' (Imerofruvat) failed to meet its primary endpoint in a clinical trial for cutaneous lupus erythematosus (CLE).


On September 23 (local time), HanAll Biopharma's global partner Immunovant announced the proof-of-concept (PoC) clinical results for Imerofruvat in CLE. In this trial of 57 patients, the change in the Cutaneous Lupus Erythematosus Disease Area and Severity Index – Activity (CLASI-A) from baseline at Week 12 did not demonstrate statistical significance compared to the placebo group.


Immunovant has decided to discontinue the development of Imerofruvat for the CLE indication, taking into account the clinical results and the current market competition.

HanAll Halts Imeroprubart Lupus Development, Focuses on Core Indications View original image

As a result of this decision, the number of indications for Imerofruvat will decrease from six to five. Clinical trials for the remaining key indications—Graves' disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and Sjogren’s syndrome (SjD)—will proceed as scheduled.


Imerofruvat is a neonatal Fc receptor (FcRn) inhibitor that reduces pathogenic IgG antibodies causing autoimmune diseases. HanAll Biopharma and Immunovant are co-developing it as a next-generation core pipeline candidate.



A HanAll Biopharma representative remarked, "In collaboration with Immunovant, we will focus all efforts on the commercialization of high-value core indications, including Graves' disease, difficult-to-treat rheumatoid arthritis, and myasthenia gravis."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing